Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

(2012) E Weisberg et al.   LEUKEMIA

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia

(2012) Niklas Feldhahn et al.   OncoImmunology

p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells

(2011) Shivashni S. Gaundar et al.   CELL CYCLE

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

(2011) E Weisberg et al.   LEUKEMIA

Smac mimetics: implications for enhancement of targeted therapies in leukemia

(2010) E Weisberg et al.   LEUKEMIA

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML

(2009) Ellen Weisberg et al.   DRUG RESISTANCE UPDATES

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

(2008) E. Weisberg et al.   BLOOD

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

(2008) E. Weisberg et al.   MOLECULAR CANCER THERAPEUTICS